CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it is accepting applications for its second annual global competitive grants program, Advocacy for Impact. This program aims to provide patient advocacy groups around the world with the flexibility to address the critical unmet needs of the diverse rare disease communities they serve.
“We were strongly encouraged by the number of applicants we received in the first year of the Advocacy for Impact grants program,” said Tiffany Patrick, Head of Global Patient Advocacy and Engagement at Alnylam. “The output from last year’s program has been impressive, and we are thrilled to continue into our second year. We look forward to seeing the creativity that advocacy groups bring to their work on behalf of patients and families around the world facing these rare diseases.”
Advocacy for Impact grants will recognize and fund new projects, each in an amount up to $50,000, that focus on serving the unmet needs of ATTR amyloidosis, acute hepatic porphyria and/or primary hyperoxaluria type 1 patients, specifically those that:
- Increase disease awareness and access to diagnosis
- Offer education to patients, families, caregivers, healthcare providers, and/or the public
- Improve patient care
To be eligible, patient advocacy groups must have charitable status and may only submit one proposal per year. Applications will be accepted via email to AdvocacyForImpact@alnylam.com from today through January 3, 2020. Eligible patient advocacy groups may submit their applications in any language. A committee of experts from within and outside of Alnylam will review each application independently. Recipients will be announced in mid-2020.
In its first year of the program, Alnylam provided $248,000 in funding to seven patient groups in six countries. One of the grant recipients, the British Porphyria Association, just recently organized the largest porphyria event to date in the UK related to mental health and well-being.
“We held an immersive and engaging event that brought together all of those connected to the porphyrias, especially those under 30 years of age, who are often socially alienated by their condition,” said Liz Gill, Vice Chair, British Porphyria Association. “This truly would not have been possible without Alnylam’s Advocacy for Impact grant!”
Additional information about these recipients and their programs can be read here. Please visit the Alnylam Advocacy for Impact grants page for additional information about the application process.
About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust discovery platform. Alnylam’s first commercial RNAi therapeutic is ONPATTRO® (patisiran), approved in the U.S., EU, Canada, Switzerland and Japan. Alnylam has a deep pipeline of investigational medicines, including five product candidates that are in late-stage development. Looking forward, Alnylam will continue to execute on its "Alnylam 2020" strategy of building a multi-product, commercial-stage biopharmaceutical company with a sustainable pipeline of RNAi-based medicines to address the needs of patients who have limited or inadequate treatment options. Alnylam employs over 1,200 people worldwide and is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on Twitter at @Alnylam or on LinkedIn.
